Methotrexate Accord (Methotrexate)

Methotrexate blocks the enzyme dihydrofolate reductase, preventing the formation of tetrahydrofolate needed for DNA synthesis. This antiproliferative action reduces the growth of immune cells and malignant cells, leading to decreased inflammation in autoimmune diseases and inhibition of cancer cell replication.

The dose of methotrexate is individualized and set by the prescribing clinician based on the specific indication, patient weight, renal function, and treatment response. Dosage regimens can vary widely, so the prescriber determines the appropriate amount and frequency.

Methotrexate is classified as Pregnancy Category X, meaning it is contraindicated in pregnancy due to a high risk of fetal toxicity and malformations. It is also not recommended during breastfeeding because it can be excreted in breast milk and may harm the infant.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity of Methotrexate Accord. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain logistics if needed) and required import documentation.

Methotrexate is often considered the first‑line conventional DMARD because of its proven efficacy, oral or injectable formulations, and relatively low cost. Compared with newer biologic agents, it has a broader safety profile and does not require routine infusion, but it may be less rapid in controlling severe disease and requires regular laboratory monitoring.

Methotrexate Accord should be stored at 2‑8 °C in a refrigerator. Keep the product in its original packaging, protect it from light, and avoid freezing or shaking the vial. If temperature excursions occur, consult the supplier before use.

Methotrexate Accord is supplied for subcutaneous injection. The injection is typically performed by a healthcare professional using aseptic technique, and the dose is administered into the fatty tissue of the abdomen or thigh according to the prescriber’s instructions.

The most serious adverse events include severe liver toxicity, pulmonary fibrosis, and bone‑marrow suppression that can lead to anemia, leukopenia or thrombocytopenia. Patients should be monitored regularly for signs of liver dysfunction, respiratory symptoms, and abnormal blood counts, and therapy should be stopped if any of these conditions develop.

Methotrexate is contraindicated in pregnant women, patients with severe renal or hepatic impairment, those with active infections, and individuals with known hypersensitivity to methotrexate or its excipients. Caution is also advised for patients with pre‑existing lung disease or a history of alcohol abuse.